The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
Curated pathway from expert analysis
flowchart TD
A["CCL2-CCR2 Axis Hypothesis<br/>ALS NMJ Selective Motor Neuron Vulnerability"]
B["Perturbation-First Validation Required<br/>Before Therapeutic Claims"]
C["CCR2 Antagonist or CRISPRi<br/>In Vivo ALS Mouse Model Testing"]
D["Motor Neuron Denervation Quantification<br/>Electrophysiology and Morphology"]
E["Mechanism Confirmation<br/>Confirm CCL2-CCR2 Dependency in ALS Model"]
F["Therapeutic Claim Validation<br/>Evidence-Supported Target Progression"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for ALS yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ALS.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.